No Data
No Data
Express News | Eli Lilly and Co reached a strategic partnership with Radionetics.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were retreating late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.4%. The iShares Biotechnology ETF (I
Fighting Words: Lilly and Novo Swat Back at the Biden/Sanders Call for Lower GLP-1 Prices
The Investment Guide for the 2024 USA Election is here! The best deployment time has come. Which US stocks are worth paying attention to?
Bank of America stated that the average monthly ROI of the S&P 500 index in the fourth year of a presidential cycle shows mediocre performance from January to May, a summer rebound from June to August, a fall before the election in September to October, and a post-election rebound in November and December.
Eli Lilly and Co finally obtained approval from the USA FDA, and there will be a two-strong competition in the field of Alzheimer's disease.
① The FDA announced on its official website that the drug “donanemab-azbt” developed by Eli Lilly has been approved to treat early-stage Alzheimer's patients with mild cognitive impairment; ② Eli Lilly executives wrote that Kisunla has shown very meaningful results, and patients urgently need this effective treatment plan.
Sector Update: Health Care
Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.4%. The iShares Biotechnology ETF (IBB)